Jagsonpal Pharmaceuticals Ltd vs Zenlabs Ethica Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 206.8 as of 05 May 15:30 . The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 12.2 on March 2021 to 25.9 on March 2025 . This represents a CAGR of 16.25% over 5 yearsThe P/E Ratio of Zenlabs Ethica Ltd changed from 17.9 on March 2021 to 76.1 on March 2025 . This represents a CAGR of 33.57% over 5 years The Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 208.41 crore on March 2021 to ₹ 1433 crore on March 2025 . This represents a CAGR of 47.06% over 5 yearsThe Market Cap of Zenlabs Ethica Ltd changed from ₹ 13.77 crore on March 2021 to ₹ 20.32 crore on March 2025 . This represents a CAGR of 8.09% over 5 years The revenue of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 67.37 crore as compare to the Dec '25 revenue of ₹ 75.92 crore. This represent the decline of -11.26% The revenue of Zenlabs Ethica Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 12.43 crore. This represent the decline of -100% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 14.33 crore as compare to the Dec '25 ebitda of ₹ 17.16 crore. This represent the decline of -16.49% The ebitda of Zenlabs Ethica Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ -1.56 crore. This represent the decline of -100% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 5.33 crore to ₹ 8.76 crore over 8 quarters. This represents a CAGR of 28.20% The net profit of Zenlabs Ethica Ltd changed from ₹ 0.04 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 yearsThe Dividend Payout of Zenlabs Ethica Ltd changed from 33.21 % on March 2023 to 0 % on March 2025 . This represents a CAGR of -100.00% over 3 years .

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

About Zenlabs Ethica Ltd

Zenlabs Ethica Limited (Formerly known Neelkanth Technologies Limited) was incorporated in 1993.
The Company is one of the top 10 pharmaceutical contract marketing and trading companies in India that markets and distribute a wide range of branded drugs including Gastrointestinal disorders, Anti-Diabetics, Anti-Hypertensive Drugs, Anti-Infective, Soaps & Anti-Bacterial Drugs, Nutraceuticals, etc., It boasts of a comprehensive global network.
It deals into marketing and distribution of pharmaceutical products and has grown to be of India's top pharmaceutical companies in 2019. The Company has been launched in collaboration with Zenlabs Pharmaceutical Inc, Canada.
The strength lies in quality, affordable and branded drugs in enhancing the quality of life of people.
Apart from this, it offers more than 600 products across therapeutic segments, making it a leader among pharmaceutical companies in India.

FAQs for the comparison of Jagsonpal Pharmaceuticals Ltd and Zenlabs Ethica Ltd

Which company has a larger market capitalization, Jagsonpal Pharmaceuticals Ltd or Zenlabs Ethica Ltd?

Market cap of Jagsonpal Pharmaceuticals Ltd is 1,425 Cr while Market cap of Zenlabs Ethica Ltd is 15 Cr

What are the key factors driving the stock performance of Jagsonpal Pharmaceuticals Ltd and Zenlabs Ethica Ltd?

The stock performance of Jagsonpal Pharmaceuticals Ltd and Zenlabs Ethica Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jagsonpal Pharmaceuticals Ltd and Zenlabs Ethica Ltd?

As of May 5, 2026, the Jagsonpal Pharmaceuticals Ltd stock price is INR ₹212.25. On the other hand, Zenlabs Ethica Ltd stock price is INR ₹23.69.

How do dividend payouts of Jagsonpal Pharmaceuticals Ltd and Zenlabs Ethica Ltd compare?

To compare the dividend payouts of Jagsonpal Pharmaceuticals Ltd and Zenlabs Ethica Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.